NEW YORK, Aug. 12, 2022 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company”), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the appointment of Dr. Suzanne Bruhn and Dr. Roger Crystal, effective August 11, 2022 as independent members of its Board of Directors. “We are pleased to welcome both…


Previous articleOpinions | Hallucinations of Meaning: If you can lie, so can psychedelics
Next articleOptimi Health Unveils Canada’s First Natural Therapeutic Psilocybin Product For Approved Patients